Roche

Roche’s flu pill Xofluza gains EU approval

Swiss pharma company Roche has scored approval from the European Commission (EC) for its flu pill Xofluza. ... We are delighted that the European Commission has approved Xofluza, a first-in-class, single-dose oral medicine, for the treatment of influenza,

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

Another competitor in the SMA market – Roche’s Evrysdi (risdiplam) – was recently approved in the US for the treatment of SMA in adults and children aged two months and older, following ... Roche has priced Evrysdi by patient weight, with a maximum

Two drugs found to reduce mortality in severe COVID-19 patients

Roche’s Actemra (tocilizumab) and Sanofi’s Kevzara (sarilumab) have been found to cut the risk of death in critically ill COVID-19 patients in a study led by Imperial College ... This includes Roche’s own phase 3 COVACTA study, in which Actemra did

Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

According to Roche, tiragolumab is the first anti-TIGIT molecule to win a BTD from the FDA. ... outcomes for people with certain types of lung cancer,” said Levi Garraway, chief medical officer and head of Global Product Development, Roche.

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

The European Commission has approved a fixed dose combination of Roche’s antibody blockbusters Herceptin and Perjeta under the new brand name Phesgo. ... In Roche’s half-year report for 2020, sales of Herceptin had dropped by 28%, reflecting the

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]